Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd.
|
|
- Dinah Osborne
- 5 years ago
- Views:
Transcription
1 Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd. - Aiming to Create New Business Models and Expand Contribution to Patients - March 29, 2018 Nichi-Iko Pharmaceutical Co., Ltd. Eisai Co., Ltd.
2 Safe Harbor Statement Materials and information provided during this presentation may contain so-called forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations. The Company cannot guarantee the actual outcomes and results for any forward-looking statements. Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The English-language presentation was translated from the original Japanese-language version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese-language version shall prevail. 1
3 Agenda Ⅰ. Nichi-Iko Pharmaceutical Co., Ltd. s Rationale for the Alliance 1. Outline and Overall Framework of the Alliance 2. Integration of Elmed Eisai and Envisioned Structure Ⅱ. Eisai Co., Ltd. s Rationale for the Alliance 1. About Elmed Eisai 2. Creating New Business Models and Expanding Contribution to Patients - Outline of Total Inclusive Ecosystem and Goals of the Alliance - 3. Strategic Alliance for API Business 2
4 Agenda Ⅰ. Nichi-Iko Pharmaceutical Co., Ltd. s Rationale for the Alliance 1. Outline and Overall Framework of the Alliance 2. Integration of Elmed Eisai and Envisioned Structure Ⅱ. Eisai Co., Ltd. s Rationale for the Alliance 1. About Elmed Eisai 2. Creating New Business Models and Expanding Contribution to Patients - Outline of Total Inclusive Ecosystem and Goals of the Alliance - 3. Strategic Alliance for API Business 3
5 Outline of the Alliance Take up the challenge of creating new business models for the generic pharmaceutical business Strategic alliance agreement to bring about growth and enhanced profit for both companies Use API CMO Eisai Vizag Plant in India API Procurement of superior price competitive API from Eisai Promotion of sustainable cost reduction measures under Profit Management Plan 2019 Leverage Eisai s API development capability and manufacturing techniques for new products as well Contract manufacturing at Vizag Plant in India with low costs and advanced technology Provide products, etc. Total Inclusive Ecosystem Nichi-Iko, who has a wide product lineup, provides products and other services Enhance Power of Development for new markets such as regional healthcare Generic Integration Enhance cost competitiveness by increasing scale Add Value-Added Generic Drugs to product lineup Capture 20% share of Japanese domestic generic market 4
6 Integration of Elmed Incremental acquisition of 17 billion yen worth of Elmed shares in total scheduled according to progress of strategic alliance agreement April 2, 2018 (planned) Nichi-Iko takes a 20% capital stake in Elmed October 1, 2018 (planned) Nichi-Iko makes additional investment in Elmed Co-promotion commences Eisai co-promotes Nichi-Iko products April 1, 2019 (planned) Nichi-Iko takes a 100% capital stake in Elmed Further promotion of Strategic Alliance 20.0% 80.0% 33.4% 66.6% Nichi-Iko co-promotes Elmed products 5 Ratio of shares held Co-promotion
7 Integration of Elmed Products Enhanced lineup 1,007 products Nichi-Iko-only products 873 products Business alliance with Eisai Overlapping products between companies 134 products Domestic generic market share Number of products 50% or over products Elmed-only products 54 products Consider co-promotion with Eisai from October 1, 2018 (planned) Between 30% and 50% 18 Between 10% and 30% 79 Cost synergies from increased scale Consider co-promotion with Nichi-Iko from October 1, 2018 (planned) 6
8 Positioning of this Agreement in the Generic Market Commanding presence in the Japanese domestic generic market Superior competitiveness Market share expansion Optimization of supply system (For reference) Simple sum of sales for Fiscal 2017 Company Nichi-Iko 12.2% Sales (millions of yen) Nichi-Iko + Elmed 191,398 Nichi-Iko 163,372 Elmed 28,026 Generic market share after the agreement is concluded 15.8% Elmed 3.6% Cost competitiveness Others 84.2% 7 Source: Internal estimates (value share based on drug prices)
9 Mission Statement Our mission is to provide value-added, high quality generic products which meet the needs of patients and their families, doctors, pharmacists, wholesalers and pharmaceutical companies in the global market as one of the most respected, well established generic companies in the world. 8
10 Agenda Ⅰ. Nichi-Iko Pharmaceutical Co., Ltd. s Rationale for the Alliance 1. Outline and Overall Framework of the Alliance 2. Integration of Elmed Eisai and Envisioned Structure Ⅱ. Eisai Co., Ltd. s Rationale for the Alliance 1. About Elmed Eisai 2. Creating New Business Models and Expanding Contribution to Patients - Outline of Total Inclusive Ecosystem and Goals of the Alliance - 3. Strategic Alliance for API Business 9
11 Company outline Founded in 1996 as a 100% subsidiary of Eisai in anticipation of necessity of low-cost and high-quality pharmaceuticals under the circumstances of increasing co-payment in elderly medicine. Since then, the company has contributed to many patients as a member of the Eisai Group by providing value-added brand generics for more than 20 years after commencing business in The company s name is derived from Elderly Medicine (Development and sales of medicines for the elderly) Sales: 28 billion yen (FY2016 results) Employees: 135 (as of March 19, 2018) <Value-added brand generics > Value in formulation: barrier-free formulations such as molded (rapidlydissolving) tablets, easily-dissolving powder/granules in water, and easy-tohandle patches, etc. Value in information: provision of information in sales collaboration with Eisai Value in economy: reduction of co-payment by patients with low-priced generics 10
12 Development as core formulation of the generic business in Eisai Development of production machine for Rapidly Disintegrating Tablets (Molded Tablets) Tableting machine for molding moistened powder Awarded the Inaugural Pharmaceutical Machinery and Engineering Prize (the Nakai Prize) 11
13 Outline of the Total Inclusive Ecosystem and Goals of the Alliance Eisai aims to create patients benefit through expansion of Total Inclusive Ecosystem, which provides necessary solutions such as medicines with patients and other stakeholders, by incorporating various contents into the platform mainly composed of the capability (i) to derive patients True Needs, (ii) to design solutions of such patients needs, and (iii) to propose Access method to such solutions as well as Outcomes (curative effect and economical efficiency) based on medical data such as evidence of clinical trial or Real World Data. Through the agreement, Nichi-Iko, who has a wide range of generic pharmaceuticals, will be added as a content provision partner. This will enhance the Total Inclusive Ecosystem for dementia, liver disease and other diseases, as well as further expand contribution to patients in regional healthcare. 12
14 13 Conceptual Image of Eisai s Total Inclusive Ecosystem for Liver Disease
15 Expanding Liver Disease Products through Strategic Alliance 14 Treatment of liver cancer Lenvima (anticancer drug ) Diagnosing imaging Iomeron (Non-ionic contrast medium) Treatment of liver cancer DC Bead (vascular embolization device) Treatment of liver cancer Cisplatin Adrenal cortical hormone Cortone Decadron Ascites Treatment (2 products) Prevention of recurrence Entecavir (Elmed) (antiviral drug) Peritonitis treatment Ciprofloxacin Spironolactone Pruritus treatment Ebastine Saccortin Combination Diagnosis of liver cancer Picolumi PIVKA-Ⅱ MONO (PIVKA-Ⅱ Kit) Hepatitis/liver cirrhosis Liver cancer patient Chlorpheniramine Maleate etc Dyslipidemia treatment Probucol Bezafibrate P Diabetes treatment ILUAMIX TELTHIA VALHYDIO etc etc Gastric and duodenal ulcer Pariet (proton pump inhibitor) Nutrition therapy Livact (branched-chain amino acid formulation) Liver supporting therapy Stronger neo-minophagen C Glycyron (treatment for chronic hepatitis) Hypertension treatment Diltiazem Hydrochloride Nicardipine Hydrochloride BEC Manidipine Hydrochloride Nifedipine Nitrendipine etc Liver supporting therapy (1 product)
16 Strategic Alliance for API Business Eisai will promote collaboration on superior API supply with Nichi-Iko on various points such as price, quality and stable supply originated from Eisai s Vizag Plant in India. Through the above, the two companies will use generics that can achieve unprecedented high quality and stable supply to fulfill their contribution to medicine. 15
17 16
LUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017
LUPIN LIMITED Investor Presentation February 09, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based
More informationRecent Trend of Generic Medicines Market In Japan
Recent Trend of Generic Medicines Market In Japan Joint 22 nd EGA and 19 th IGBA Annual Conference Dubrovnik, Croatia 9 June, 2016 Itsuro Yoshida President of Japan Generic Medicines Association Copyright
More informationShionogi to Announce Corporate Reorganization and Personnel Reassignment
Shionogi to Announce Corporate Reorganization and Personnel Reassignment Osaka, Japan, February 28, 2018 - Shionogi & Co., Ltd. (Head : Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter Shionogi
More informationFeature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in
Feature Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia Based on our long-term strategic vision toward 2020, our goal is to become #1 in Asia in terms of our
More informationDigital Health Startups A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationHorizon Societal Challenge 1: Health, demographic change and wellbeing. Jeremy Bray DG Research & Innovation European Commission
Horizon 2020 Societal Challenge 1: Health, demographic change and wellbeing Jeremy Bray DG Research & Innovation European Commission National NHS day Leeds, UK, 29 January 2014 What is Horizon 2020? The
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More informationAbbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO
Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking
More informationConfirms 2013 Financial Guidance
Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared
More informationLocal Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background
Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationTextron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported
More information[Overview of the Consolidated Financial Results]
0 1 [Overview of the Consolidated Financial Results] 1. Consolidated revenue totaled 5,108.3 billion yen, increased by 581.1 billion yen (+12.8%) from the previous year. 2. Consolidated operating profit
More informationChapter 5. Forms of Business Ownership and Organization
Chapter 5 Forms of Business Ownership and Organization Learning Objectives 1 2 Discuss why most businesses are small businesses. Determine the contributions of small businesses to the economy. 7 Outline
More information18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*)
18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*) Research Fellow: Kenta Kosaka In the pharmaceutical industry, the development of new drugs not only requires
More informationSony IR Day Game & Network Services Segment. November 25, Andrew House
Sony IR Day 2014 November 25, 2014 Andrew House President and Group CEO Sony Computer Entertainment Inc. Group Executive in Charge of Network Entertainment Business Sony Corporation Agenda 1. Business
More informationSecurity and Risk Assessment in GDPR: from policy to implementation
Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is
More informationTextron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%
Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third
More informationNASDAQ: CASI Partnering Presentation
NASDAQ: CASI Partnering Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to
More informationTextron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook
Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS
More informationA Message from the President
A Message from the President Since its establishment in 1928, Minolta has been a pioneer of light-related technology development in a growing number of fields. Currently, society is undergoing great changes
More informationASEAN: A Growth Centre in the Global Economy
Bank Negara Malaysia Governor Dr. Zeti Akhtar Aziz Speech at the ASEAN SME Conference 2015 It is my pleasure to be here this afternoon to speak at this inaugural ASEAN SME Conference. This conference takes
More informationDealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.
Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:
More informationRationale for the proposed transaction
PRESS RELEASE Fortis Healthcare Limited Board of Directors approves demerger of its diagnostics business into a separate listed Company through a composite scheme of arrangement Gurgaon, August 19, 2016
More informationTRIUMF ACCELERATING CANADIAN BUSINESS THROUGH SCIENCE AND INNOVATION Pre-Budget Consultation
Canada s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules TRIUMF ACCELERATING CANADIAN BUSINESS THROUGH
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More information4. Vision 2: Providing innovative drugs to 8 billion people worldwide
4. Vision 2: Providing innovative drugs to 8 billion people worldwide Strategic points for realizing the vision Responding to diverse needs and issues [Advanced countries] Promoting understanding of the
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationResults Briefing Session
Results Briefing Session The First-Half of the Fiscal Year Ending March 31, 2010 November 5, 2009 1 SQUARE ENIX HOLDINGS CO., LTD. Statements made in this document with respect to SQUARE ENIX HOLDINGS
More informationPharmaceutical Enterprises' R&D Strategic Alliance the Road for Small and Medium Sized Pharmaceutical Enterprises' R&D in China
Pharmaceutical Enterprises' R&D Strategic Alliance the Road for Small and Medium Sized Pharmaceutical Enterprises' R&D in China Shuzhen Chu, Chunmei Sun & Chun Liang School of International Pharmaceutical
More informationCRS Report for Congress
95-150 SPR Updated November 17, 1998 CRS Report for Congress Received through the CRS Web Cooperative Research and Development Agreements (CRADAs) Wendy H. Schacht Specialist in Science and Technology
More informationDaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector
More informationDriving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China
Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant
More information$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance
Reynolds American Enters Smokeless Tobacco Category Via Acquisition of Conwood $3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category Deal at a Glance 2005 Financial Summary
More informationAndalusian Agency for Health Technology Assessment (AETSA)
Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationCapcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, rd Quarter Report Fiscal year ending March 31, 2010
Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, 9697 3rd Quarter Report Fiscal year ending March 31, 2010 Precautions Concerning Forward-looking Statements Strategies, plans, outlooks and other
More informationShell Project Delivery Best Practices Dick L. Wynberg, GM NOV Projects Integrated Gas Shell Global Solutions International B.V
Shell Project Delivery Best Practices Dick L. Wynberg, GM NOV Projects Integrated Gas Shell Global Solutions International B.V SEPTEMBER 26, 2017, ST. PETERSBURG, HOTEL ASTORIA Definitions and cautionary
More informationParenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)
Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about
More informationJ.P. Morgan Healthcare Conference Summary Transcript
J.P. Morgan Healthcare Conference Summary Transcript Good afternoon, everyone. I'm Shigeo Taniuchi. I'm President and COO of Santen Pharmaceutical. I joined Santen in 1996, and I became the President and
More information'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint
'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationHealthTech: What does it mean for compliance?
HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15
More informationCollegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
More informationFY2007 First-Half Period Results Briefing Session. November 19, 2007
FY2007 First-Half Period Results Briefing Session November 19, 2007 1 Statements made in this document with respect to SQUARE ENIX CO., LTD. and consolidated subsidiaries' (together, "SQUARE ENIX") plans,
More informationTechnology and Innovation in the NHS Highlands and Islands Enterprise
Technology and Innovation in the NHS Highlands and Islands Enterprise Introduction Highlands and Islands Enterprise (HIE) welcomes the opportunity to respond to the Committee s call for views. We recognise
More informationFY2004 Results Briefing Session. May 24, 2005
FY2004 Results Briefing Session May 24, 2005 1 Statements made in this document with respect to SQUARE ENIX CO., LTD. and consolidated subsidiaries' (together, "SQUARE ENIX") plans, estimates, strategies
More informationEmcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationALANCO TECHNOLOGIES INC
SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution
More informationPerspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,
More informationEU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
More information2010/IPEG/SYM/003 Measures for Encouraging Patent Licensing - INPIT Challenges
2010/IPEG/SYM/003 Measures for Encouraging Patent Licensing - INPIT Challenges Submitted by: Japan Innovating Intellectual Property Exploitation Symposium Sendai, Japan 9 September 2010 September 9, 2010
More informationAcquisition of GEODynamics. December 13, 2017
Acquisition of GEODynamics December 13, 2017 Forward-looking Statements We include the following cautionary statement to take advantage of the "safe harbor" provisions of the Private Securities Litigation
More informationElectrical Products Group Conference
Electrical Products Group Conference Scott C. Donnelly Chairman, President and CEO Forward-Looking Information Certain statements in today s discussion will be forward-looking statements, including those
More informationFY2005 Results Briefing Session. May 24, 2006
FY2005 Results Briefing Session May 24, 2006 1 Statements made in this document with respect to SQUARE ENIX CO., LTD. and consolidated subsidiaries' (together, "SQUARE ENIX") plans, estimates, strategies
More informationEpilogue. Simona Rocchi Erasmus University, Centre for Environmental Studies, Rotterdam
Simona Rocchi Erasmus University, Centre for Environmental Studies, Rotterdam Epilogue Enhancing Sustainable Innovation by Design An Approach to the Co-creation of Economic, Social and Environmental Value
More informationGLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT
GLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT CRITICAL THINKING AT THE CRITICAL TIME ABOUT US The Global Risk and Investigations Practice (GRIP) of FTI Consulting is the leading provider of
More informationImplementation of Systems Medicine across Europe
THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation
More informationAdvancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation
Advancing Health and Prosperity A Brief to the Advisory Panel on Healthcare Innovation November 2014 About ITAC ITAC is the voice of the Canadian information and communications technologies (ICT) industry
More information25 th Workshop of the EURORDIS Round Table of Companies (ERTC)
25 th Workshop of the EURORDIS Round Table of Companies (ERTC) Healthcare Companies & European Reference Networks: Expectations & Potential for Collaboration Introduction Tuesday 26 September, 2017 (09:00
More informationin Developing Countries in FY2008
Study on Economic Partnership Projects in Developing Countries in FY2008 Study on Research and Development Center for Space Technology of Vietnam Academy of Science and Technology in Hoa Lac in Socialist
More informationKKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn
More informationMedicines Manufacturing in the UK 2017
Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership
More informationThe game market is expanding worldwide and Capcom continues to grow due to mobile and download sales
Explanation Summary for the Briefing Regarding Financial Results of the Year ending March 31, 2015 by Haruhiro Tsujimoto, President and COO (May 8, 2015) I am Haruhiro Tsujimoto, president and chief operating
More informationThe Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages
The Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages Ludovico Alcorta UNU-MERIT alcorta@merit.unu.edu www.merit.unu.edu Agenda Formulating STI policy STI policy/instrument
More informationGE OIL & GAS ANNUAL MEETING 2016 Florence, Italy, 1-2 February
GE OIL & GAS ANNUAL MEETING 2016 Florence, Italy, 1-2 February Value creation and partnership in a challenging business environment Harry Brekelmans Projects and Technology Director Royal Dutch Shell 2016
More informationOperational Intelligence to Deliver Smart Solutions. Copyright 2015 OSIsoft, LLC
Operational Intelligence to Deliver Smart Solutions Presented by John de Koning DEFINITIONS AND CAUTIONARY NOTE Reserves: Our use of the term reserves in this presentation means SEC proved oil and gas
More informationKonica Minolta Group MANAGEMENT POLICY <09-10>
Konica Minolta Group MANAGEMENT POLICY Masatoshi Matsuzaki President and CEO Konica Minolta Holdings, Inc. May 14, 2009 Cautionary Statement: The forecasts mentioned in this material are the results
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationCONTACTS: Michaela Hessling Executive Director Corporate Communications Tel
Aurubis continues developing its strategy Group working on a more effective organization, an increase in productivity and a sustainable improvement in earnings Resolution for dividend payment of 1.10 per
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationCapcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2017
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2017 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements
More informationOperational Intelligence to deliver Smart Solutions
Operational Intelligence to deliver Smart Solutions Presented by John de Koning Shell Global Solutions DEFINITIONS AND CAUTIONARY NOTE Reserves: Our use of the term reserves in this presentation means
More informationLupin Limited Annual Results FY12. Investor Presentation May being
Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR
More informationNEWS RELEASE. Life sciences companies tout their expertise in India
For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More informationKaro Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
More informationCapcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2019
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2019 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements
More informationdemonstrator approach real market conditions would be useful to provide a unified partner search instrument for the CIP programme
Contribution by the Ministry of Industry and Trade of the Czech Republic to the public consultations on a successor programme to the Competitiveness and Innovation Framework Programme (CIP) 2007-2013 Given
More informationianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital
August 14, 2017 ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital To Acquire One of Ten License Holders in New
More informationHalliburton and Baker Hughes Creating the leading oilfield services company
Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com
More informationclarification to bring legal certainty to these issues have been voiced in various position papers and statements.
ESR Statement on the European Commission s proposal for a Regulation on the protection of individuals with regard to the processing of personal data on the free movement of such data (General Data Protection
More informationStatement of Corporate Intent
2018-23 Statement of Corporate Intent Building and maintaining Australia s frontline naval assets. www.asc.com.au 02 STATEMENT OF CORPORATE INTENT 2018-2023 ASC Pty Ltd About ASC ASC Pty Ltd is a proprietary
More informationColombia on the Frontier of Biomedicine. Zagaya
Colombia on the Frontier of Biomedicine An Intersectorial Meeting for Research, Innovation and Health February 27 & 28, 2012 Hotel Intercontinental, Cali, Colombia Kay Monroe, Executive Director Zagaya
More informationDraft executive summaries to target groups on industrial energy efficiency and material substitution in carbonintensive
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft executive summaries to target groups on industrial energy efficiency and material substitution
More informationGlobalisation increasingly affects how companies in OECD countries
ISBN 978-92-64-04767-9 Open Innovation in Global Networks OECD 2008 Executive Summary Globalisation increasingly affects how companies in OECD countries operate, compete and innovate, both at home and
More informationKansai Paint Co., Ltd.
To Shareholders with Voting Rights Securities Code: 4613 June 7, 2018 33-1 Kanzaki-cho, Amagasaki, Hyogo (Head office: 6-14 Imabashi 2-chome, Chuo-ku, Osaka) Hiroshi Ishino Representative Director, President
More informationTransition PPT Template. J.P. Morgan. June 2015 V 3.0. Energy Equity Conference June 27, 2017
Transition PPT Template J.P. Morgan June 2015 V 3.0 Energy Equity Conference 2017 June 27, 2017 Forward-Looking Statements This presentation contains forward-looking statements, including, in particular,
More informationHealth Innovations in Horizon 2020: the framework programme for research and innovation ( )
Health Innovations in Horizon 2020: the framework programme for research and innovation (2014-2020) Virginija Dambrauskaite, MD, PhD Scientific Officer, Medical Research Unit, Health Directorate Directorate-General
More informationPROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS
PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA
More informationFOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationTable Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements
More informationAcquisition of MST Medical Surgery Technologies Ltd:
Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation
More informationPresentation. March 2007
Presentation March 2007 1 Corporate Overview 2 Corporate Overview Leading provider of research-driven packaging solutions solely-focused on pharmaceutical industry Founded in 1994 and based in Pune, India
More informationThe resulting net sales were 87,170 million yen (up 13.2% from the previous fiscal year).
Attachment contents 1. Operating results overview 2 (1) Operating results for the fiscal year under review. 2 (2) Financial position overview for the fiscal year under review. 4 (3) Cash flow overview
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More information